Newport Beach-based Acacia Research Corp. said last week it has acquired a patent for stent graft technology on undisclosed terms.
Stent grafts are devices that open up blood vessels for surgery and are most commonly used in coronary arteries.
Acacia has been on a patent-buying spree this year and has recently targeted the medical device and diagnostic sectors for growth, according to Chief Executive Paul Ryan.
The company now controls more than 200 patent portfolios.
Acacia is undergoing a strategic shift to buy patents outright rather than licensing technology on behalf of companies. In February it raised $225 million through a stock sale to private investors to fund its growth strategy.
The company saw about $172 million in sales in 2011, up 31% from 2010.
Acacia’s publicly traded shares had a recent market value of about $1.33 billion.
—Chris Casacchia
